


PHARMACEUTICAL 2023

Cus.com - the alternative .com

Biofrontera Inc. Rank 207 of 446







PHARMACEUTICAL 2023

Biofrontera Inc. Rank 207 of 446

The relative strengths and weaknesses of Biofrontera Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Biofrontera Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 97% points. The greatest weakness of Biofrontera Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 43% points.

The company's Economic Capital Ratio, given in the ranking table, is 104%, being 61% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	43,140
Cost of Goods Sold	0
Intangible Assets	3,032
Liabilities, Current	20,894
Liabilities, Non-Current	869
Other Assets	4,508
Other Compr. Net Income	0
Other Expenses	12,150
Other Liabilities	5,243
Other Net Income	17,973
Other Revenues	28,674
Property and Equipment	204
Research and Development	0
Selling, General and Administrative Expense	35,137

Output Variable	Value in 1000 USD
Assets	50,884
Liabilities	27,006
Expenses	47,287
Revenues	28,674
Stockholders Equity	23,878
Net Income	-640
Comprehensive Net Income	-640
Economic Capital Ratio	104%

